EMERALD2

CONDITION

Cancer

GENDER

Both males and females

AGE GROUP

18 years and above

TRIAL STATUS

Recruiting

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center, global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab monotherapy or placebo as adjuvant therapy. This study will be conducted in patients with HCC who are at high risk of recurrence after curative hepatic resection or ablation.

CONTACT DETAILS

Phone Number: (08) 9242 7640
Email: nursing@affinityresearch.com.au
Location: 42/95 Monash Avenue, Nedlands WA, Australia

CONTACT SITE

Approved By: Bellberry              

Clinical Trial Registry Link: Click Here